Recombinant human TSH versus hypothyroidism: Cost-minimization-analysis in the follow-up care of differentiated thyroid carcinoma

NuklearMedizin

Volumn 49, Issue 6, 2010, Pages 216-224

  Dietlein, M ^a   Busemeyer, S ^a   Kobe, C ^a   Schmidt, M ^a   Theissen, P ^a   Schicha, H ^a  

^a Klinik Uña Poliklinik für Nuklearmedizin Des   (Germany)

Author keywords

131i whole body scan; Hypothyroidism; RhTSH; Thyroid cancer

Indexed keywords

IODINE 131; LEVOTHYROXINE; LIOTHYRONINE; RECOMBINANT THYROTROPIN; THYROID HORMONE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PATIENT; CHILD; CONSULTATION; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST MINIMIZATION ANALYSIS; DAILY LIFE ACTIVITY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIATED THYROID CANCER; DRUG COST; FAMILY; FATIGUE; FEMALE; FOLLOW UP; HORMONAL REGULATION; HUMAN; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; MALE; PATIENT PREFERENCE; QUESTIONNAIRE; RETROSPECTIVE STUDY; SALARY; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; SYMPTOM; THYROID CANCER; THYROID FOLLICULAR CARCINOMA; THYROID HORMONE WITHDRAWAL; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; TREATMENT WITHDRAWAL; WEIGHT GAIN; WHOLE BODY SCINTISCANNING; WORKING TIME;

FATIGUE; FEMALE; HOSPITALIZATION; HUMANS; HYPOTHYROIDISM; MALE; RECOMBINANT PROTEINS; THYROGLOBULIN; THYROID NEOPLASMS; THYROTROPIN; THYROTROPIN ALFA;

EID: 78650775640     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.3413/nukmed-0321-1005     Document Type: Article

References (37)

1. Biermann M, Pixberg MK, Riemann B et al. Clinical outcome of adjuvant external-beam radiotherapy for differentiated thyroid cancer. Results after 874 patient-years of follow-up in the MSDS-trial. Nuklearmedizin 2009; 48: 89-98.
2. Blamey S, Barraclough B, Delbridge L et al. Using recombinant human thyroid-stimulating hormone for the diagnosis of recurrent thyroid cancer. ANZ J Surg 2005; 75: 10-20. (Pubitemid 40394697)
3. Borget I, Corone C, Nocaudie M et al. Sick leave for follow-up control in thyroid cancer patients: Comparison between stimulation with thyrogen and thyroid hormone withdrawal. Eur J Endocrinol 2007; 156: 531-538. (Pubitemid 46796519)
4. Botella-Carretero JI, Gomez-Bueno M, Barrios V et al. Chronic thyrotropin-suppressive therapy with levothyroxine and short-term overt hypothyroidism after thyroxine withdrawal are associated with undesirable cardiovascular effects in patients with differentiated thyroid carcinoma. Endocr-Relat Cancer 2004; 11: 345-356. (Pubitemid 38832835)
5. th ed. Lippincott, Williams and Wilkins: 855.
6. Busemeyer S. Rekombinantes humanes TSH in der Nachsorge des differenzierten Schilddrüsenkarzinoms. Inaugural-Dissertation. Medizinische Fakultät der Universität zu Köln 2009.
7. Cohen O, Dabhi S, Karasik A et al. Compliance with follow-up and the informative value of diagnostic whole-body scan in patients with differentiated thyroid carcinoma given recombinant human TSH. Eur J Endocrin 2004; 150: 285-290. (Pubitemid 38443777)
8. Constant EL, De Volder AG, Ivanoiu A et al. Cerebral blood flow and glucose metabolism in hypothyroidism: a positron emission tomography study. J Clin Endocrinol Metab 2001; 86: 3864-3870. (Pubitemid 32755990)
9. Cooper DS, Doherty GM, Haugen BR et al. Revised American Thyroid Association Management Guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19: 1167-1214.
10. Dedecjus M, Kolomecki K, Brzezinski J et al. Influence of L-thyroxine administration on poor-platelet plasma VEGF concentrations in patients with induced short-term hypothyroidism, monitored for thyroid carcinoma. Endocrine J 2007; 54: 63-69. (Pubitemid 46481673)
11. Den Hollander JG, Wulkan RW, Mantel MJ et al. Correlation between severity of thyroid dysfunction and renal function. Clin Endocrinol 2005; 62: 423-427. (Pubitemid 40503368)
12. Dietlein M, Dressler J, Eschner W et al. Procedure guideline for iodine-131 whole-body scintigraphy for differentiated thyroid cancer (version 3). Nuklearmedizin 2007; 46: 206-212. (Pubitemid 47612287)
13. Dietlein M, Dressler J, Eschner W et al. Procedure guidelines for radioiodine therapy of differentiated thyroid cancer (Version 3). Nuklearmedizin 2007; 46: 213-219. (Pubitemid 47612288)
14. Dow KH, Ferrell BR, Anello C Quality of life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy. Thyroid 1997; 7: 613-619.
15. Dueren C, Dietlein M, Luster M et al. The use of Thyrogen® in the treatment of differentiated thyroid carcinoma: An intraindividual comparison of clinical effects and implications of daily life. Exp Clin Endocrinol Diabetes 2010; 118: 513-519.
16. Duntas LH, Biondi B. Short-term hypothyroidism after Levothyroxine- withdrawal in patients with differentiated thyroid cancer: clinical and quality of life consequences. Eur J Endocrinol 2007; 156: 13-19. (Pubitemid 46553899)
17. Haugen BR, Pacini F, Reiners C et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 1999; 84: 3877-3885. (Pubitemid 30644169)
18. Koopmanschap MA, Rutten FFH, van Ineveld BM et al. The friction cost method for measuring indirect costs of disease. J Health Econ 1995; 14: 171-189.
19. Lorenz R, Dietlein M, Reiners C. Stationäre nuklearmedizinische Therapie in Deutschland- Analyse der strukturierten Qualitätsberichte 2004 bis 2008. Nuklearmedizin 2010; 49: 49-57.
20. Luster M, Felbinger R, Dietlein M et al. Thyroid hormone withdrawal in patients with differentiated thyroid carcinoma: a one hundred thirty-patient pilot survey on consequences of hypothyroidism and a pharmacoeconomic comparison to recombinant thyrotropin administration. Thyroid 2005; 15: 1147-1155. (Pubitemid 41720721)
21. Luster M, Clarke SE, Dietlein M et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2008; 35: 1941-1959.
22. Mazzaferri EL. An overview of the management of papillary and follicular thyroid carcinoma. Thyroid 1999; 9: 421-427. (Pubitemid 29244917)
23. Mernagh P, Campbell S, Dietlein M et al. Cost-effectiveness of using recombinant human TSH prior to radioiodine ablation for thyroid cancer, compared with treating patients in a hypothyroid state: the German perspective. Eur J Endocrinol 2006; 155: 405-414. (Pubitemid 44463946)
24. Munte TF, Lill C, Otting G et al. Cognitive changes in short-term hypothyroidism assessed with eventrelated brain potentials. Psychoneuroendocrinology 2004; 29: 1109-1118. (Pubitemid 38829172)
25. Nijhuis TF, van Weperen W, de Klerk JMH: Costs associated with the withdrawal of thyroid hormone suppression therapy during the follow-up treatment of well-differentiated thyroid cancer. Tijdschr Nucl Geneeskd 1999; 21: 98-100.
26. Pacini F, Schlumberger M, Dralle H et al. European Consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006; 154: 787-803.
27. Pacini F, Castagna MG. Diagnostic and therapeutic use of recombinant human TSH (rhTSH) in differentiated thyroid cancer. Best Pract Res Clin Endocrinol Metab 2008; 22: 1009-1021.
28. Pacini F, Castagna MG, Brilli L et al. Differentiated thyroid cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20: 143-146.
29. 4 withdrawal in patients totally thyreoidectomized for thyroid cancer. J Endocrinol Invest 2006; 29: 32-40.
30. Schicha H, Hellmich M, Lehmacher W et al. Should all patients with thyroid nodules ≥ 1 cm undergo fine-needle aspiration biopsy? Nuklearmedizin 2009; 48: 79-83.
31. Schlumberger MJ, Incerti C, Pacini F et al. The role of recombinant thyroid-stimulating hormone (rhTSH) in the detection and management of welldifferentiated thyroid carcinoma: A roundtable discussion. J Endocrinol Invest 1999; 22: 35-41.
32. Schroeder PR, Haugen BR, Pacini F et al. A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. J Clin Endocrinol Metab 2006; 91: 878-884.
33. Tagay S, Herpertz S, Langkafel M et al. Health-related quality of life, anxiety and depression in thyroid cancer patients under short-term hypothyroidism and TSH-suppressive levothyroxine treatment. Eur J Endocrinol 2005; 153: 755-763. (Pubitemid 43020225)
34. Taieb D, Sebag F, Cherenko M et al. Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation (RRA) with recombinant human TSH (rhTSH): a randomized controlled study. Clin Endocrinol 2009; 71: 115-123.
35. Thomsen AF, Kvist TK, Andersen PK et al. Increased risk of developing affective disorder in patients with hypothyroidism: a register-based study. Thyroid 2005; 15: 700-707. (Pubitemid 41117523)
36. Verburg FA, de Keizer B, de Klerk JMH et al. Value of diagnostic radioiodine scintigraphy and thyroglobulin measurement after rhTSH injection. Nuklearmedizin 2009; 48: 26-29.
37. 131I. Nuklearmedizin 2009; 48: 138-142.